Connection

Co-Authors

This is a "connection" page, showing publications co-authored by GORDON B MILLS and SHUYING LIU.
Connection Strength

2.227
  1. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle. 2009 Nov 15; 8(22):3695-701.
    View in: PubMed
    Score: 0.351
  2. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell. 2009 Jun 02; 15(6):539-50.
    View in: PubMed
    Score: 0.340
  3. Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A. 2008 Apr 01; 105(13):5248-53.
    View in: PubMed
    Score: 0.314
  4. Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Mol Cancer Ther. 2019 02; 18(2):399-412.
    View in: PubMed
    Score: 0.165
  5. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14.
    View in: PubMed
    Score: 0.127
  6. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget. 2014 Oct 15; 5(19):9049-64.
    View in: PubMed
    Score: 0.123
  7. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst. 2008 Nov 19; 100(22):1630-42.
    View in: PubMed
    Score: 0.082
  8. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol. 2007; 433:1-25.
    View in: PubMed
    Score: 0.072
  9. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin Cancer Res. 2006 Nov 15; 12(22):6598-602.
    View in: PubMed
    Score: 0.071
  10. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem. 2004 Dec 03; 279(49):51075-81.
    View in: PubMed
    Score: 0.062
  11. Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem. 2004 Aug 15; 92(6):1115-40.
    View in: PubMed
    Score: 0.061
  12. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004 Mar 05; 279(10):9653-61.
    View in: PubMed
    Score: 0.058
  13. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer?. Ann Oncol. 2014 Jun; 25(6):1122-7.
    View in: PubMed
    Score: 0.030
  14. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2014 Feb; 23(2):316-23.
    View in: PubMed
    Score: 0.029
  15. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013 Sep 26; 4(6):1116-30.
    View in: PubMed
    Score: 0.029
  16. Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol. 2013 Oct; 24(10):2522-2526.
    View in: PubMed
    Score: 0.028
  17. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol. 2013 Apr; 24(4):909-16.
    View in: PubMed
    Score: 0.027
  18. Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol. 2012 May; 26(5):786-97.
    View in: PubMed
    Score: 0.026
  19. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77.
    View in: PubMed
    Score: 0.026
  20. Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res. 2012 Feb 15; 18(4):1109-19.
    View in: PubMed
    Score: 0.025
  21. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res. 2011 Nov 01; 71(21):6773-84.
    View in: PubMed
    Score: 0.025
  22. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011 Jun; 10(6):1093-101.
    View in: PubMed
    Score: 0.024
  23. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011 Mar 01; 71(5):1871-82.
    View in: PubMed
    Score: 0.024
  24. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res. 2011 Mar 01; 17(5):1082-9.
    View in: PubMed
    Score: 0.024
  25. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem. 2009 Mar 13; 284(11):7385-94.
    View in: PubMed
    Score: 0.021
  26. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol. 2007 Aug; 31(2):441-9.
    View in: PubMed
    Score: 0.019
  27. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006 Mar 01; 66(5):2740-8.
    View in: PubMed
    Score: 0.017
  28. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene. 2003 May 15; 22(19):2897-909.
    View in: PubMed
    Score: 0.014
  29. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem. 2003 Apr 04; 278(14):11962-9.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.